Free Trial
LON:OXB

Oxford Biomedica (OXB) Share Price, News & Analysis

Oxford Biomedica logo
GBX 299 -5.00 (-1.64%)
As of 04/17/2025 11:56 AM Eastern

About Oxford Biomedica Stock (LON:OXB)

Key Stats

Today's Range
293.50
307.50
50-Day Range
232.50
391
52-Week Range
190
455
Volume
111,308 shs
Average Volume
299,389 shs
Market Capitalization
£317.84 million
P/E Ratio
N/A
Dividend Yield
4.57%
Price Target
GBX 560
Consensus Rating
Moderate Buy

Company Overview

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

Oxford Biomedica Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

OXB MarketRank™: 

Oxford Biomedica scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oxford Biomedica has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Oxford Biomedica has received no research coverage in the past 90 days.

  • Read more about Oxford Biomedica's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oxford Biomedica is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oxford Biomedica is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oxford Biomedica has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for OXB.
  • Dividend Leadership

    Oxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Oxford Biomedica does not have a long track record of dividend growth.

  • Read more about Oxford Biomedica's dividend.
  • Short Interest

    There is no current short interest data available for OXB.
  • News Sentiment

    Oxford Biomedica has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Oxford Biomedica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.17% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.13% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oxford Biomedica's insider trading history.
Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

OXB Stock News Headlines

Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
See More Headlines

OXB Stock Analysis - Frequently Asked Questions

Oxford Biomedica's stock was trading at GBX 420 at the beginning of 2025. Since then, OXB shares have decreased by 28.8% and is now trading at GBX 299.
View the best growth stocks for 2025 here
.

Oxford Biomedica plc (LON:OXB) released its quarterly earnings results on Wednesday, April, 9th. The biopharmaceutical company reported ($41.75) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative trailing twelve-month return on equity of 202.50% and a negative net margin of 145.98%.
Read the conference call transcript
.

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF) and Barclays (BARC).

Company Calendar

Last Earnings
4/09/2025
Today
4/20/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:OXB
CIK
N/A
Fax
N/A
Employees
891
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 560
High Stock Price Target
GBX 740
Low Stock Price Target
GBX 380
Potential Upside/Downside
+87.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-143,513,452.58
Net Margins
-145.98%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£98.31 million
Cash Flow
GBX 99.45 per share
Price / Cash Flow
3.01
Book Value
GBX 67.70 per share
Price / Book
4.42

Miscellaneous

Free Float
N/A
Market Cap
£317.84 million
Optionable
Not Optionable
Beta
1.09
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (LON:OXB) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners